Drug Profile
Cytomegalovirus immune globulin - Biotest
Alternative Names: BT-094; CMV-Gyn; CMVIG; Cytotect; Cytotect 70; Cytotect CP; Cytotect CP Biotest; Cytotect FH; HCMV-specific hyperimmune globulin - Biotest; Human cytomegalovirus immunoglobulin; Human normal immunoglobulin; Megalotect; NeocytotectLatest Information Update: 18 Nov 2022
Price :
$50
*
At a glance
- Originator Biotest
- Developer Biotest AG
- Class Antivirals; Immunoglobulins
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Cytomegalovirus infections
Most Recent Events
- 13 Sep 2022 Biotest in collaboration with University Hospital initiates a phase II trial for Cytomegalovirus infections in France (NCT05370976)
- 12 May 2022 Biotest and University Hospital plans a phase II trial for Cytomegalovirus infections (Prevention) (IV,Infusion) in September 2022 (NCT05370976)
- 25 Apr 2022 Biotest AG has been acquired by Grifols